Xencor, Inc. (NASDAQ:XNCR) Shares Bought by Summit Investment Advisors Inc.

Summit Investment Advisors Inc. increased its holdings in Xencor, Inc. (NASDAQ:XNCR) by 22.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 7,045 shares of the biopharmaceutical company’s stock after purchasing an additional 1,282 shares during the period. Summit Investment Advisors Inc.’s holdings in Xencor were worth $162,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in XNCR. Sterling Capital Management LLC grew its position in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the period. GAMMA Investing LLC increased its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares during the last quarter. KBC Group NV increased its holdings in Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,337 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of Xencor in the 4th quarter valued at about $239,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. William Blair started coverage on Xencor in a research report on Monday. They set an “outperform” rating for the company. Finally, StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.86.

Xencor Stock Performance

XNCR opened at $10.65 on Wednesday. Xencor, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The firm has a market cap of $750.42 million, a PE ratio of -3.33 and a beta of 0.90. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $12.10 and a 200-day simple moving average of $18.60.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. As a group, equities analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.